Covis Pharma is a global specialty pharmaceutical company

Our patients are our paramount concern. We market therapeutic solutions for patients with life-threatening conditions and chronic illnesses

Team

Covis is led by one of the strongest and longest-tenured senior management teams committed to delivering therapeutic solutions to improve the lives of its patients.

Strategic Partners

Through its operational excellence, Covis is the preferred partner to world-class pharmaceutical companies and contract manufacturing organizations.

Product Portfolio

Covis offers a portfolio of pharmaceutical products providing patients with affordable and therapeutically equivalent medications of select brands.

About Covis

At Covis, our paramount concern is patients' outcomes as we focus on improving the health of people with serious medical conditions.

Covis is always evaluating products and corporate acquisition opportunities. Covis is well-capitalized and has significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities.

Company and Product History

Team

Dean Mitchell is the Chairman of the Board of Covis Pharma Holdings ‐ the parent company of Covis Pharma. He has built successful pharmaceutical businesses in both the public and private sector and is an expert at strategic planning and product development.

Prior to joining Covis Holdings, Dean served as President and CEO of Lux Biosciences and held senior positions at Bristol-Myers Squibb as well as GlaxoSmithKline.

Dean Mitchell holds an MBA degree from City University Business School, London, England, and a B.S. degree in Applied Biology from Coventry University, UK.

Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Alexander Mironov is the Senior Vice President of Business Development and M&A. He brings over 14 years of business development and regulatory affairs experience with a number of private equity funded specialty pharmaceutical companies.

Prior to Covis, Alexander was with Pernix Therapeutics where he was a Senior Vice President of Corporate Development leading identification, evaluation, and negotiation of product and company acquisitions. Previous positions with increased responsibility were with companies such as Alvogen, EKR Therapeutics, Esprit Pharma and Valera Pharmaceuticals. Alexander began his career with Pfizer.

Alexander received his BS from Rutgers University with a concentration in Biochemistry. In addition, he completed Executive Management Training in Private Equity/ Venture Capital at Harvard Business School. Alexander speaks fluent English and Russian.

Aziza Johnson is the Senior Vice President of Regulatory and Scientific Affairs. She has over 18 years of progressive global regulatory experience in the pharmaceutical industry leading project teams from early development through to commercial launch. Aziza has been active in all her roles and has led projects through start up, launch, survival, and growth.

Prior to Covis, Aziza worked in a variety of environments (small, medium, and large pharmaceutical organizations) with increasing roles and responsibility and in more recent years, including management roles. In addition, Aziza worked at the Medicines and Healthcare Regulatory Agency as a pharmaceutical assessor, where she gained useful insight into the operations of the UK Regulatory agency. Aziza attended the University of London School of Pharmacy and the University of Leicester where she received her B.Pharm. (Hons.) and Masters in Law respectively.

Fabio Fazio is Senior Vice President, Quality Assurance and Qualified Person. He ensures compliance of pharmaceutical production to good manufacturing practice and to Marketing Authorizations. Fabio is responsible for the implementation of the quality systems which include the management of regulatory inspections, supplier oversight and audits, technology transfers, QP release of medicinal products to market, and adherence to good distribution practice.

Prior to Covis, Fabio worked at Biogen Idec as Qualified Person and in other technical CMC roles. Previous experiences encompass Process Development at GlaxoSmithKline in support of early stage clinical trials and basic research of novel therapeutic agents at the Scripps Research Institute in La Jolla, CA.

Fabio graduated from the Faculty of Pharmacy at the University of Siena, Italy, and received his Ph.D. in Chemistry from the University of Wuppertal, Germany.

Al Tenuto is the Senior Vice President of Market Access for Covis Pharma. He has more than 20 years of experience in the pharmaceutical industry and more than 15 years focused on the payer, distribution, pricing and government reporting.

Prior to Covis, Al was with Vivus where he was the Vice President of Market Access focused on the commercial launch of Qsymia. Al spent much of his career with Eli Lilly & Company in a variety of leadership positions with responsibility on the US payer and getting products to market through the US supply chain. Al attended the University of Miami where he received a BA in Marine Affairs.

Christian Calcagno is the Vice President of Business Development and M&A. Previously, he was a VP at Cerberus Capital Management where he held multiple senior management operating roles at Covis Pharma within M&A and Corporate Finance. Christian focused on the Covis investment throughout his tenure at Cerberus playing an integral role in the growth of Covis through its many acquisitions and partial monetization of the business for $1.2 billion.

Prior to joining Cerberus, Christian was with Ernst & Young in their Transaction Advisory Services practice performing valuations and financial and operational due diligence.

Christian holds a Bachelor of Science in Mechanical Engineering from Lehigh University. Christian speaks fluent English and Spanish.

Joan Fuste is the Vice President of Finance. He has over 15 years of international experience in Finance, Controlling and Business Strategy with Fortune 500 organizations in the Healthcare and FMCG industries.

Prior to Covis, Joan worked in several Finance positions of increased responsibility for companies such as Johnson & Johnson and Abbott Laboratories. He is internationally experienced in business integration and change in different cultural environments, working in countries like Germany, Belgium, Spain, Switzerland and the UK.

Joan graduated with a degree in Business Administration at the University of Barcelona and holds a Postgraduate degree in Finance from the UPF University. He also studied International Business at San Diego State University in California. Joan speaks English, Spanish, Catalan, French and German.

Dean Mitchell is the Chairman of the Board of Covis Pharma Holdings ‐ the parent company of Covis Pharma. He has built successful pharmaceutical businesses in both the public and private sector and is an expert at strategic planning and product development.

Prior to joining Covis Holdings, Dean served as President and CEO of Lux Biosciences and held senior positions at Bristol-Myers Squibb as well as GlaxoSmithKline.

Dean Mitchell holds an MBA degree from City University Business School, London, England, and a B.S. degree in Applied Biology from Coventry University, UK.

Brett Ingersoll serves as Co-Head and Senior Managing Director of Cerberus Capital Management, L.P.'s Private Equity Group, and is also a member of the Cerberus Capital Management Investment Committee. Brett currently sits on the boards of PaxVax Global, Covis Pharma Holdings S.a.r.l., Steward Healthcare, and DynCorp International. Brett is a graduate of Brigham Young University and received an MBA from Harvard Business School.

Jim Lenehan is a Senior Operations advisor to Cerberus Capital Management, L.P. Prior to Cerberus, he was Vice Chairman and President of Johnson & Johnson. Jim held various executive positions at Johnson & Johnson during his 28-year tenure, including President of McNeil Consumer Products Company and Worldwide Chairman, Consumer Pharmaceuticals & Professional Group. Jim is also a member of the board of Covis Pharma Holdings S.a.r.l., Steward Healthcare and Medtronic. Jim earned his B.A. in economics from the University of Akron and his MBA from Northwestern.

Barry is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Barry was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Barry was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Barry identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton's products to new medical uses, and spearheaded programs to develop these new indications.

Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Dr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering's Office of Technology. Before Berlex, Dr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company's Radiation Safety Officer. Dr. Levinson received his PhD and Master's degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.

Mike Palmer is a Senior Vice President of Cerberus Capital Management, L.P.'s Private Equity Group. Mike focuses primarily on transactions involved in healthcare, media, telecommunications, and consumer products. Mike is based in Cerberus' New York office. Mike has played an important role in a number of Cerberus investments and currently sits on the boards of PaxVax Global, Covis Pharma Holdings S.a.r.l., and Print Media Holdings. Mike received a B.S. in Economics from Duke University, where he graduated cum laude.

Michael is a Managing Director at Princeton Biopharma Capital Partners, LLC a boutique private equity firm focused on providing growth capital and operating expertise to commercial stage healthcare companies. He is a veteran of the pharmaceutical industry with extensive expertise in licensing and commercialization of prescription pharmaceuticals around the world. Prior to forming Princeton Biopharma Capital, LLC, he was the founder and CEO of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan diseases. Michael started the company in 2004 with a blank piece of paper and a dream. By 2010, the company was on track to surpass $100 million in revenue and $35 million of EBITDA with 11 products sold in over 30 countries. In 2010 the company was sold to Valeant Pharmaceuticals International for $330 million. In 2009 Michael was a winner of the Ernst & Young Entrepreneur of the Year Award.

Prior to forming Aton, Michael co-founded Lathian Systems Inc., a venture-backed company that provides online data and marketing services to pharmaceutical and biotech companies. At Lathian, he held several senior management positions, including Vice President of Marketing, Vice President of Sales, Vice President of Operations and Director. His career began at Merck & Co. Inc., where he held positions ranging from hospital sales to brand management. He holds a BS and MS from the University of Pittsburgh and an MBA from The Wharton School.

Team

Leadership Team

Dean Mitchell is the Chairman of the Board of Covis Pharma Holdings ‐ the parent company of Covis Pharma. He has built successful pharmaceutical businesses in both the public and private sector and is an expert at strategic planning and product development.

Prior to joining Covis Holdings, Dean served as President and CEO of Lux Biosciences and held senior positions at Bristol-Myers Squibb as well as GlaxoSmithKline.

Dean Mitchell holds an MBA degree from City University Business School, London, England, and a B.S. degree in Applied Biology from Coventry University, UK.

Michael Porter is the CEO of Covis Pharma. Previously he was COO of Covis Pharma Sarl, where he was responsible for the partial monetization of the business for $1.2 billion. He has over 20 years of private equity experience. Prior to Covis, Michael was with Cerberus Capital Management where he was a Senior Operating Executive.

He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group.

Michael received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Michael speaks English, Spanish, Portuguese, French, Japanese, and Russian.

Alexander Mironov is the Senior Vice President of Business Development and M&A. He brings over 14 years of business development and regulatory affairs experience with a number of private equity funded specialty pharmaceutical companies.

Prior to Covis, Alexander was with Pernix Therapeutics where he was a Senior Vice President of Corporate Development leading identification, evaluation, and negotiation of product and company acquisitions. Previous positions with increased responsibility were with companies such as Alvogen, EKR Therapeutics, Esprit Pharma and Valera Pharmaceuticals. Alexander began his career with Pfizer.

Alexander received his BS from Rutgers University with a concentration in Biochemistry. In addition, he completed Executive Management Training in Private Equity/ Venture Capital at Harvard Business School. Alexander speaks fluent English and Russian.

Aziza Johnson is the VP of Regulatory Affairs. She has over 18 years of progressive global regulatory experience in the pharmaceutical industry leading project teams from early development through to commercial launch. Aziza has been active in all her roles and has led projects through start up, launch, survival, and growth.

Prior to Covis, Aziza worked in a variety of environments (small, medium, and large pharmaceutical organizations) with increasing roles and responsibility and in more recent years, including management roles. In addition, Aziza worked at the Medicines and Healthcare Regulatory Agency as a pharmaceutical assessor, where she gained useful insight into the operations of the UK Regulatory agency. Aziza attended the University of London School of Pharmacy and the University of Leicester where she received her B.Pharm. (Hons.) and Masters in Law respectively.

Fabio Fazio is the VP of Quality Assurance. He ensures compliance of pharmaceutical production to good manufacturing practice and to Marketing Authorizations. Fabio is responsible for the implementation of the quality systems which include the management of regulatory inspections, supplier oversight and audits, technology transfers, QP release of medicinal products to market, and adherence to good distribution practice.

Prior to Covis, Fabio worked at Biogen Idec as Qualified Person and in other technical CMC roles. Previous experiences encompass Process Development at GlaxoSmithKline in support of early stage clinical trials and basic research of novel therapeutic agents at the Scripps Research Institute in La Jolla, CA.

Fabio graduated from the Faculty of Pharmacy at the University of Siena, Italy, and received his Ph.D. in Chemistry from the University of Wuppertal, Germany.

Al Tenuto is the Senior VP of Market Access for Covis Pharma. He has more than 20 years of experience in the pharmaceutical industry and more than 15 years focused on the payer, distribution, pricing and government reporting.

Prior to Covis, Al was with Vivus where he was the Vice President of Market Access focused on the commercial launch of Qsymia. Al spent much of his career with Eli Lilly & Company in a variety of leadership positions with responsibility on the US payer and getting products to market through the US supply chain. Al attended the University of Miami where he received a BA in Marine Affairs.

Christian Calcagno is the VP of Business Development and M&A. Previously, he was a VP at Cerberus Capital Management where he held multiple senior management operating roles at Covis Pharma within M&A and Corporate Finance. Christian focused on the Covis investment throughout his tenure at Cerberus playing an integral role in the growth of Covis through its many acquisitions and partial monetization of the business for $1.2 billion.

Prior to joining Cerberus, Christian was with Ernst & Young in their Transaction Advisory Services practice performing valuations and financial and operational due diligence.

Christian holds a Bachelor of Science in Mechanical Engineering from Lehigh University. Christian speaks fluent English and Spanish.

Joan Fuste is the Director of Finance. He has over 15 years of international experience in Finance, Controlling and Business Strategy with Fortune 500 organizations in the Healthcare and FMCG industries.

Prior to Covis, Joan worked in several Finance positions of increased responsibility for companies such as Johnson & Johnson and Abbott Laboratories. He is internationally experienced in business integration and change in different cultural environments, working in countries like Germany, Belgium, Spain, Switzerland and the UK.

Joan graduated with a degree in Business Administration at the University of Barcelona and holds a Postgraduate degree in Finance from the UPF University. He also studied International Business at San Diego State University in California. Joan speaks English, Spanish, Catalan, French and German.

Board of Directors

Dean Mitchell is the Chairman of the Board of Covis Pharma Holdings ‐ the parent company of Covis Pharma. He has built successful pharmaceutical businesses in both the public and private sector and is an expert at strategic planning and product development.

Prior to joining Covis Holdings, Dean served as President and CEO of Lux Biosciences and held senior positions at Bristol-Myers Squibb as well as GlaxoSmithKline.

Dean Mitchell holds an MBA degree from City University Business School, London, England, and a B.S. degree in Applied Biology from Coventry University, UK.

Brett Ingersoll serves as Co-Head and Senior Managing Director of Cerberus Capital Management, L.P.'s Private Equity Group, and is also a member of the Cerberus Capital Management Investment Committee. Brett currently sits on the boards of PaxVax Global, Covis Pharma Holdings S.a.r.l., Steward Healthcare, and DynCorp International. Brett is a graduate of Brigham Young University and received an MBA from Harvard Business School.

Jim Lenehan is a Senior Operations advisor to Cerberus Capital Management, L.P. Prior to Cerberus, he was Vice Chairman and President of Johnson & Johnson. Jim held various executive positions at Johnson & Johnson during his 28-year tenure, including President of McNeil Consumer Products Company and Worldwide Chairman, Consumer Pharmaceuticals & Professional Group. Jim is also a member of the board of Covis Pharma Holdings S.a.r.l., Steward Healthcare and Medtronic. Jim earned his B.A. in economics from the University of Akron and his MBA from Northwestern.

Barry is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Barry was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Barry was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Barry identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton's products to new medical uses, and spearheaded programs to develop these new indications.

Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Dr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering's Office of Technology. Before Berlex, Dr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company's Radiation Safety Officer. Dr. Levinson received his PhD and Master's degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.

Mike Palmer is a Senior Vice President of Cerberus Capital Management, L.P.'s Private Equity Group. Mike focuses primarily on transactions involved in healthcare, media, telecommunications, and consumer products. Mike is based in Cerberus' New York office. Mike has played an important role in a number of Cerberus investments and currently sits on the boards of PaxVax Global, Covis Pharma Holdings S.a.r.l., and Print Media Holdings. Mike received a B.S. in Economics from Duke University, where he graduated cum laude.

Michael is a Managing Director at Princeton Biopharma Capital Partners, LLC a boutique private equity firm focused on providing growth capital and operating expertise to commercial stage healthcare companies. He is a veteran of the pharmaceutical industry with extensive expertise in licensing and commercialization of prescription pharmaceuticals around the world. Prior to forming Princeton Biopharma Capital, LLC, he was the founder and CEO of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan diseases. Michael started the company in 2004 with a blank piece of paper and a dream. By 2010, the company was on track to surpass $100 million in revenue and $35 million of EBITDA with 11 products sold in over 30 countries. In 2010 the company was sold to Valeant Pharmaceuticals International for $330 million. In 2009 Michael was a winner of the Ernst & Young Entrepreneur of the Year Award.

Prior to forming Aton, Michael co-founded Lathian Systems Inc., a venture-backed company that provides online data and marketing services to pharmaceutical and biotech companies. At Lathian, he held several senior management positions, including Vice President of Marketing, Vice President of Sales, Vice President of Operations and Director. His career began at Merck & Co. Inc., where he held positions ranging from hospital sales to brand management. He holds a BS and MS from the University of Pittsburgh and an MBA from The Wharton School.

Partnerships

We partner with the world's leading pharmaceutical companies and contract manufacturing organizations to deliver an uninterrupted supply of high-quality pharmaceuticals.

Operational Capabilities

Covis has unparalleled expertise across all functional areas with a flawless history of executing commercial onboarding, tech transferring, and launching authorized generic and line extension products.

Business Development

Covis is always evaluating products and corporate acquisition opportunities with significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities. For all partnering inquiries, please contact us.

Product Development

Covis is devoted to developing new therapeutic solutions to improve patients' quality of life through line extensions of its existing portfolio as well as selected novel late-stage clinical programs.

Our Operating Partners

Our Business Development Partners

Our Authorized Distributors of Record

Products

Product information is intended for residents of the United States only. Lanoxin® is a registered trademark of the GlaxoSmithKline group of companies. Rilutek® is a registered trademark of the Sanofi-Aventis group of companies. Betapace® and BetapaceAF® are registered trademarks of BAYER Schering Pharma AG. Altoprev® is a registered trademark of Shionogi Inc. Sular® is a registered trademark of Shionogi Inc. Alvesco®, Omnaris®, and Zetonna® are registered trademarks of Takeda GmbH.

Co-Pay

Covis' co-pay program ensures patients always have access to their therapy of choice.

News

Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma

Concordia Healthcare to buy some assets of Covis Pharma for $1.2 billion

Covis Pharma to Acquire US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®